Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Accart, Nathalie ^a   Urosevic Maiwald, Mirjana ^c   Dummer, Reinhard ^c   Bataille, Vincent ^a   Kehrer, Nadine ^a   Niculescu, Cristina ^a   Limacher, Jean Marc ^a   Chenard, Marie Pierre ^b   Bonnefoy, Jean Yves ^d   Rooke, Ronald ^a  

^a TRANSGENE S A   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d ElsaLys Biotech   (France)

Author keywords

Cutaneous lymphoma; Cytotoxicity; Lymphocytes; TG1042

Indexed keywords

ANTINEOPLASTIC AGENT; TG 1042; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; B CELL LYMPHOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS B CELL LYMPHOMA; CUTANEOUS T CELL LYMPHOMA; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; OUTCOME ASSESSMENT; PRIMARY TUMOR; SKIN BIOPSY; SKIN LYMPHOMA; TUMOR MICROENVIRONMENT;

DISEASE PROGRESSION; GENETIC VECTORS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, T-CELL, CUTANEOUS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84884508177     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-226     Document Type: Article

References (24)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785. 10.1182/blood-2004-09-3502, 15692063.
2. Dummer R, Willers J, Kamarashev J, Urosevic M, Dobbeling U, Burg G. Pathogenesis of cutaneous lymphomas. Semin Cutan Med Surg 2000, 19:78-86. 10.1016/S1085-5629(00)80003-6, 10892708.
3. Nagatani T, Kim S, Baba N, Miyamoto H, Minato K, Shimoyama M, Nakajima H. Phenotypic heterogeneity of lymphoma of the skin. J Dermatol 1989, 16:443-452.
4. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007, 110:1713-1722. 10.1182/blood-2007-03-055749, 17540844.
5. Gilliam AC, Wood GS. Primary cutaneous lymphomas other than mycosis fungoides. Semin Oncol 1999, 26:290-306.
6. Parks JD, Synovec MS, Masih AS, Braddock SW, Nakamine H, Sanger WG, Harrington DS, Weisenburger DD. Immunophenotypic and genotypic characterization of lymphomatoid papulosis. J Am Acad Dermatol 1992, 26:968-975. 10.1016/0190-9622(92)70143-4, 1607417.
7. Beljaards RC, Meijer CJ, Van der Putte SC, Hollema H, Geerts ML, Bezemer PD, Willemze R. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma. J Pathol 1994, 172:53-60. 10.1002/path.1711720110, 7931828.
8. Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases. Cancer 1991, 67:2311-2326. 10.1002/1097-0142(19910501)67:9<2311::AID-CNCR2820670918>3.0.CO;2-0, 2013039.
9. Yang B, Tubbs RR, Finn W, Carlson A, Pettay J, Hsi ED. Clinicopathologic reassessment of primary cutaneous B-cell lymphomas with immunophenotypic and molecular genetic characterization. Am J Surg Pathol 2000, 24:694-702. 10.1097/00000478-200005000-00008, 10800988.
10. Dummer R, Goldinger SM, Cozzio A, French LE, Karpova MB. Cutaneous lymphomas: molecular pathways leading to new drugs. J Invest Dermatol 2012, 132:517-525. 10.1038/jid.2011.370, 22158559.
11. Rook AH, Junkins-Hopkins JM, McGinnis KS, Wysocka M, Richardson SK, Budgin JB, Everitts S, Vittorio CC. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma. Adv Dermatol 2002, 18:29-43.
12. Bunn PA, Foon KA, Ihde DC, Longo DL, Eddy J, Winkler CF, Veach SR, Zeffren J, Sherwin S, Oldham R. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984, 101:484-487. 10.7326/0003-4819-101-4-484, 6332565.
13. Kaplan EH, Rosen ST, Norris DB, Roenigk HH, Saks SR, Bunn PA. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990, 82:208-212. 10.1093/jnci/82.3.208, 2104937.
14. Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999, 94:902-908.
15. Cope A, Le Friec G, Cardone J, Kemper C. The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching. Trends Immunol 2011, 32:278-286. 10.1016/j.it.2011.03.010, 21531623.
16. Dummer R, Hassel JC, Fellenberg F, Eichmuller S, Maier T, Slos P, Acres B, Bleuzen P, Bataille V, Squiban P, et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004, 104:1631-1638. 10.1182/blood-2004-01-0360, 15161670.
17. Dummer R, Eichmuller S, Gellrich S, Assaf C, Dreno B, Schiller M, Dereure O, Baudard M, Bagot M, Khammari A, et al. Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther 2010, 18:1244-1247. 10.1038/mt.2010.52, 2889748, 20372104.
18. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1089-1107.
19. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992, 99:90-94. 10.1111/1523-1747.ep12611877, 1607682.
20. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004, 75:163-189.
21. Seo N, Tokura Y, Matsumoto K, Furukawa F, Takigawa M. Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sezary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity. Clin Exp Immunol 1998, 112:403-409. 10.1046/j.1365-2249.1998.00599.x, 1904995, 9649208.
22. Trudel S, Li Z, Dodgson C, Nanji S, Wan Y, Voralia M, Hitt M, Gauldie J, Graham FL, Stewart AK. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma-a phase 1 study. Leukemia 2001, 15:846-854. 10.1038/sj.leu.2402077, 11368448.
23. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002, 13:95-109. 10.1016/S1359-6101(01)00038-7, 11900986.
24. Murphy KM, Ouyang W, Farrar JD, Yang J, Ranganath S, Asnagli H, Afkarian M, Murphy TL. Signaling and transcription in T helper development. Annu Rev Immunol 2000, 18:451-494. 10.1146/annurev.immunol.18.1.451, 10837066.